Core Insights - A strategic collaboration has been established among InSilico Medicine, Maiwei Biotech, and Haoyuan Pharmaceutical to develop a new library of ADC compounds targeting hundreds of antigens, aiming to accelerate the industrialization of innovative ADC drugs [1][2][3] Group 1: Collaboration Details - The partnership is based on the principles of complementary advantages, resource sharing, collaborative innovation, and mutual benefits [1] - Maiwei Biotech will provide access to hundreds of monoclonal and multi-antibody combinations along with its proprietary ADC technology platform, covering various disease areas such as tumors and autoimmune diseases [1][2] - InSilico Medicine will leverage its Pharma.AI platform to design innovative payload-linkers based on disease mechanisms and target characteristics, showcasing the advantages of AI in drug development [2] Group 2: Industry Impact - This collaboration represents a significant innovation breakthrough in China's biopharmaceutical industry within the ADC drug sector, integrating AI technology with traditional drug development [2] - The partnership aims to create a complete value chain for ADC drug development, enhancing efficiency by shortening the molecular optimization process that traditionally takes years [2] - The collaboration is expected to provide more effective and safer treatment options for global patients by accelerating the development of ADC drugs [3]

Core Insights - A strategic cooperation agreement has been established among InSilico Medicine, Maiwei Biotech, and Haoyuan Pharmaceutical to develop a new library of ADC compounds targeting hundreds of antigens, aiming to accelerate the industrialization of innovative ADC drugs [1][2] Group 1: Company Contributions - Maiwei Biotech possesses an internationally leading ADC drug development platform that has been clinically validated, showcasing strong R&D capabilities and commercialization potential [1] - InSilico Medicine will utilize its Pharma.AI platform to design innovative payload-linkers based on disease mechanisms and target characteristics, demonstrating the advantages of AI in drug development [2] - Haoyuan Pharmaceutical will provide a rich resource library of molecular building blocks and tool compounds to support the synthesis of ADC payload-linkers, facilitating a full-process collaboration from screening to clinical development [2] Group 2: Industry Impact - This collaboration represents an innovative breakthrough in China's biopharmaceutical industry within the ADC drug sector, integrating AI technology with traditional drug development to create a new model for ADC drug development [2] - The partnership aims to significantly shorten the molecular optimization process, which traditionally takes years, thereby enhancing R&D efficiency [2] - The collaboration establishes a complete value chain for ADC drug development, maximizing the strengths of each party to efficiently advance innovation and provide more treatment options for global patients [2][3]

Group 1 - The strategic cooperation agreement was signed between Insilico Medicine, Maiwei Biotech, and Haoyuan Pharmaceutical to develop a new ADC compound library covering hundreds of targets, aiming to accelerate the industrialization of innovative ADC drugs [1][2] - Maiwei Biotech possesses an internationally leading ADC drug development platform with clinical validation, providing a strong R&D capability and commercial potential for the collaboration [1][2] - Insilico Medicine will utilize its Pharma.AI platform to design innovative payload-linkers based on disease mechanisms and target characteristics, showcasing the advantages of AI in drug development [2][3] Group 2 - The collaboration represents an innovative breakthrough in China's biopharmaceutical industry within the ADC drug field, integrating AI technology with traditional drug development processes [2] - The partnership aims to create a complete value chain for ADC drug development, enhancing efficiency and quality in the research and development process [2][3] - The CEOs of the involved companies emphasized the importance of this collaboration in accelerating the development of ADC drugs and providing better treatment options for cancer patients globally [3]

Summary of the Conference Call on Maiwei Biotech and the Tracer Project Company and Industry Overview - **Company**: Maiwei Biotech - **Industry**: Neurodegenerative Diseases, specifically focusing on Parkinson's Disease (PD) and Multiple System Atrophy (MSA) through the Tracer project [2][4] Key Points and Arguments 1. **Tracer Project Overview**: - Tracer is a novel radiolabeled small molecule drug targeting PD and MSA, with significant application potential and a clear clinical development path [2][4] - It is the only team globally developing such a tracer for PD, aiming to be the first approved tracer for this condition [2][4] 2. **Funding and Support**: - The project has received unconditional funding from the MicroG Fox Foundation, indicating strong scientific and commercial backing [2][5] - Collaboration with top research institutions, including the Chinese Academy of Sciences, enhances the project's credibility and potential [2][6] 3. **Clinical Development Timeline**: - FDA IND approval is expected in 2025, with the first patient enrollment planned for Q4 2025 [5][6] - The Chinese IND is anticipated to be approved in early 2026, with over 100 patient imaging studies already conducted at Huashan Hospital [5][6] 4. **Market Potential**: - The Tracer project targets a large unmet market for PD, with no similar products currently approved, positioning Maiwei Biotech to set new treatment standards [6][10] - The project is expected to solidify Maiwei's position in the chronic disease sector, particularly in age-related diseases [6][10] 5. **Operational Model**: - Maiwei is the largest external investor in the project, which operates independently but leverages Maiwei's core operational capabilities [3][8] - The company plans to explore overseas licensing and transfer opportunities as the project matures [9][20] 6. **Clinical Trial Design**: - Phase I trials will focus on safety, radiation dosimetry, and pharmacokinetics, with a target enrollment of 20 to 30 patients [15][22] - The project faces challenges in obtaining post-mortem data for validation, which may require international collaboration [15][22] 7. **Challenges in Commercialization**: - High costs and lack of insurance coverage for PD diagnostics may hinder market acceptance [15][18] - The company plans to integrate diagnostic tools with therapeutic drugs to enhance market uptake [15][18] 8. **AI Integration**: - AI technology is being explored to improve imaging analysis and diagnostic accuracy, potentially increasing market penetration [16][18] 9. **Future Development Plans**: - Maiwei is committed to expanding its pipeline in neurodegenerative diseases, including Alzheimer's, while adopting differentiated strategies to enhance drug development efficiency [14][24] 10. **Shareholding Structure**: - Maiwei holds a 35% stake in the Tracer project, with plans to potentially increase investment to meet clinical needs and achieve commercialization [23][24] Additional Important Insights - The Tracer project is positioned as a first-in-class solution in the PD space, with significant implications for future investment returns compared to the Alzheimer's market, which has multiple approved tracers [10][12] - The collaboration with international partners and the establishment of a robust BD network are crucial for the project's success and future opportunities [11][19]

Core Viewpoint - The strategic collaboration among Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical aims to develop a novel ADC compound library targeting hundreds of sites, accelerating the industrialization of innovative ADC drugs [1] Group 1: Company Collaboration - Maiwei Biotech, Yingshi Intelligent, and Haoyuan Pharmaceutical have officially announced a strategic cooperation agreement [1] - The partnership focuses on screening and advancing next-generation ADC candidate molecules [1] - The collaboration is expected to enhance the innovation and commercialization of ADC drugs [1]

锚定"四新"赛道 产业集聚效应凸显 金秋九月，北国春城长春迎来一场聚焦产业升级的盛会。9月19日至20日，由中国投资协会、上海证券 报、长春新区管委会联合主办的"创新转型，'吉'聚动能"——2025长春新材料与医药行业交流会举行。 国内外上市公司高管、金融投资机构负责人、院校专家及行业协会代表等百余位嘉宾齐聚长春，通过实 地考察与深度座谈，共探合作新机遇，共谋发展新路径。 北国春城 "吉"聚动能 ——多方联动共探长春新材料与医药产业发展新机遇 为进一步促进产业交流与合作，此次活动安排了实地考察与专题交流环节。9月19日下午，与会嘉宾先 后走进长春新质生产力促进中心、长光卫星技术股份有限公司和长春新区规划展览馆，通过现场观摩与 交流，深入了解长春新区在培育新质生产力、推动科技创新与产业升级等方面的创新实践与发展潜力。 "老工业基地焕发的创新活力令人振奋。"多位与会嘉宾表示，从顶层规划到企业实践，从科研突破到产 业转化，长春新区在创新生态、产业集聚和营商环境建设方面的成果令人印象深刻。 在全球科技创新与产业变革加速融合的背景下，新材料与生物医药作为战略性新兴产业，正成为推动经 济高质量发展的重要引擎。吉林作为我国 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market" [5] Core Insights - The new drug sector has shown significant movements, with notable increases in stock prices for companies such as Kintor Pharmaceutical, which recently went public in Hong Kong, focusing on unmet clinical needs in oncology and immunology [2][3][21] - The KRAS G12D inhibitor GFH375 from Kintor Pharmaceutical has demonstrated promising clinical data in treating pancreatic cancer and non-small cell lung cancer (NSCLC), with an overall response rate (ORR) of 52% in pancreatic cancer and 68.8% in NSCLC [21][24] Summary by Sections Weekly New Drug Market Review - From September 15 to September 21, 2025, the top five gainers in the new drug sector included Kintor Pharmaceutical (+19.64%), Boan Biotechnology (+8.89%), and others, while the top five losers included Sanofi Pharmaceuticals (-17.16%) and others [1][13] Recommended Stocks to Watch - The report suggests focusing on several potential catalysts in the sector, including academic conferences and insurance negotiations. Key companies to watch include: 1. Differentiated GLP-1 assets: Zai Lab, EQRx, and others 2. Upgraded PD-1 products: CanSino Biologics and others 3. Companies likely to benefit from insurance negotiations: Hengrui Medicine, Kanghong Pharmaceutical, and others [2][17] New Drug Approval and Acceptance - This week, eight new drug applications were approved, and twelve new drug applications were accepted in China [3][25] Clinical Application Approvals - A total of 48 new drug clinical applications were approved, with 32 applications accepted this week [7][29]

Group 1: Semiconductor Industry - Semiconductor Manufacturing International Corporation (SMIC) is testing DUV lithography machines from Shanghai startup Yulian Sheng, with promising initial results for 7nm process technology [1] - Yulian Sheng is a joint venture between Shanghai Kechuang Group's subsidiary Chuangke Micro and Huawei's subsidiary New Kai, marking its first media appearance [1] - Key suppliers for Yulian Sheng include Yongxin Optical and Wavelength Optics, with Yongxin being a dark horse in the lithography machine supply chain, showing strong performance and lower valuation compared to Maolai Optical [1] Group 2: Domestic Computing Chip Market - Domestic computing chips are experiencing a surge, with Alibaba's Tianshu and Baidu's Kunlun chips winning significant contracts in domestic operator procurement [1] - The domestic computing industry chain is gaining momentum, potentially becoming a market focus, as the adoption of domestic chips may lead to new solutions rather than copying Nvidia's models [1] - Potential investment targets include Inspur Information (server manufacturing) and LightSpeed Technology (optical devices) [1] Group 3: Oil and Shipping Industry - The Middle East situation is escalating, with increased attacks from Israel, leading to tighter oil tanker supply and demand dynamics, especially as October approaches [3][4] - OPEC+ is expected to release an additional 1.65 million barrels per day in October, which will stabilize demand [4] - Low oil prices are driving global refinery restocking, with China's crude oil imports rising to approximately 11.65 million barrels per day in August, providing crucial support for demand [4] Group 4: Shipping Dynamics - The deterioration of relations between Europe and Russia due to the Ukraine conflict is reducing short-haul oil transport routes, while increasing long-haul routes from the Middle East and the Americas to the Far East [5] - The increase in VLCC (Very Large Crude Carrier) oil transport demand is expected to normalize freight rates, benefiting Chinese shipowners like COSCO Shipping Energy [5] Group 5: Federal Reserve Interest Rate Decision - The Federal Reserve is anticipated to lower interest rates by 25 basis points, with a potential surprise of 50 basis points, impacting market sentiment [6] - A rate cut is expected to benefit Hong Kong stocks, CROs, and the real estate sector, with a focus on state-owned enterprises for stability [7] - The biotech sector may see improved financing conditions, particularly benefiting companies with higher overseas receivables [7]

Group 1 - The core viewpoint of the article emphasizes the ongoing developments related to the essential drug catalog, indicating that while the release has been delayed, it is expected to occur soon, with a focus on unique essential drugs that are anticipated to grow faster than non-essential drugs [11][20][21] - The article highlights the performance of the pharmaceutical sector, noting that the CITIC pharmaceutical index fell by 1.98%, underperforming the CSI 300 index by 1.54 percentage points, ranking 22nd among 30 primary industries [8][9] - The article discusses the investment opportunities in the pharmaceutical sector, particularly in traditional Chinese medicine, state-owned enterprise reforms, and the impact of the new medical insurance catalog on OTC companies [11][14][29] Group 2 - The article provides a detailed overview of the essential drug catalog selection process, which includes expert evaluations and consultations to ensure that the selected drugs meet clinical and economic criteria [34] - It presents data on the historical changes in the essential drug catalog, showing a gradual increase in the number of traditional Chinese medicine products included, with a notable shift towards unique products since the 2009 version [17][18] - The article outlines the sales performance of newly included unique essential drugs, indicating significant growth rates for certain products, particularly in the pediatric and respiratory categories [30][32]

Investment Rating - The report maintains an optimistic outlook on the pharmaceutical industry, suggesting a potential for diverse investment opportunities by 2025 [10]. Core Insights - The pharmaceutical sector is currently undervalued, with public funds showing low allocation to this sector. Positive macroeconomic factors, such as the recovery of U.S. Treasury rates, are expected to drive growth in the industry [10]. - The report emphasizes a shift from quantity to quality in the domestic innovative drug sector, highlighting the importance of products that can generate profits. Companies such as BeiGene, Innovent Biologics, and others are recommended for investment [10]. - In the medical device sector, there is a notable recovery in bidding for imaging equipment, and home medical devices are expected to benefit from subsidy policies. Companies like Mindray and Yuwell are highlighted as key players [10]. - The report discusses the potential for growth in the CXO and life sciences services sectors, with expectations of a rebound in domestic investment and a return to high growth rates by 2025 [10]. - The traditional Chinese medicine sector is expected to see significant growth due to the upcoming updates to the essential drug list, with companies like Kunming Pharmaceutical and Kangyuan Pharmaceutical recommended for attention [12][31]. Summary by Sections Market Review - The report notes a 1.98% decline in the CITIC Pharmaceutical Index, underperforming the CSI 300 Index by 1.54 percentage points, ranking 22nd among 30 sectors [7]. - The top-performing stocks include Yino Science, Furuida, and Chengda Pharmaceutical, while the worst performers include Anglikang and Nuo Cheng Jianhua [7]. Industry and Stock Events - The report highlights the ongoing work related to the essential drug list, with expectations for updates that will favor innovative and traditional Chinese medicines [13][15]. - The essential drug list has not been updated since 2018, and the report anticipates a dynamic management approach to future updates [13]. Overall Perspective and Investment Themes - The report suggests that the pharmaceutical industry is entering a new growth cycle, particularly in the specialty raw materials sector, which is currently at a near-decade low in valuation [10]. - The report emphasizes the importance of the essential drug list in promoting reasonable drug use and its integration into hospital performance assessments [19]. - The report identifies several categories of products likely to be included in the essential drug list, including unique proprietary drugs and innovative traditional Chinese medicines [31][33].